arrow
S

Stefano Rusconi

asst ovest milano
H指数:46
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry

病毒学结局、耐药谱和病毒进化:基于lenacapavir的治疗方案在治疗经验丰富的患者中的表现——PRESTIGIO登记研究数据

2026-10-280
OAAI
Clinical management of pregnancy, delivery and breastfeeding in women living with HIV in Italy: A survey of participating infectious diseases centres

意大利HIV感染者妊娠期、分娩期及哺乳期临床管理:参与性传染病中心的调查

2026-09-150
PRE
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens

在切换至现代方案时,DNA储存的突变对病毒学抑制状态下人类免疫缺陷病毒感染者(PWH)的病毒学反应的影响

2025-11-150
OAAI
Use of fexinidazole in gambiense human African trypanosomiasis: a retrospective analysis of cases treated in Lui Hospital, South Sudan (2018–2024)

在冈比亚人非洲锥虫病中使用非尼那唑:对南苏丹卢伊医院2018-2024年治疗病例的回顾性分析

2025-09-040
OAAI
The effect of cognitive fusion on mental health and occupational burnout among health care workers during the SARS CoV-2 outbreak

认知融合对SARS CoV-2疫情期间医疗保健工作者心理健康和职业倦怠的影响

2025-08-190
OAAI
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort

长效卡博特格拉韦/利匹韦林治疗中断的有效性及预测因素:来自Icona队列的真实世界数据,用于研究病毒学受抑制的HIV感染者

2025-06-011
PRE
Cefiderocol for Gram-negative infections: comparing monotherapy and combination therapy in the multicenter CEFI-BAC study

西地尼布用于革兰氏阴性菌感染:比较多中心CEFI-BAC研究中单药疗法与联合疗法

2025-04-240
OA
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors

抗逆转录病毒治疗初治个体中,低频整合酶链转移抑制剂耐药突变对病毒学结局的影响

2025-04-100
OA
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort

比较dolutegravir/拉米夫定与bictegravir/恩曲他滨/替诺福韦阿拉酚胺富马酸盐作为一线方案的长期有效性和安全性: 一个真实的多中心队列

2024-10-302
PRE